Change Healthcare Inc. CHNG
We take great care to ensure that the data presented and summarized in this overview for Change Healthcare Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CHNG
View all-
Sarissa Consulting LLC Santa Monica, CA139KShares$03.94% of portfolio
-
Eaton Vance Management Boston, MA95.5KShares$00.0% of portfolio
-
Alphasimplex Group, LLC Boston, MA8.48KShares$02.36% of portfolio
-
Wipfli Financial Advisors Llc,220Shares$00.0% of portfolio
-
Exane Derivatives8Shares$00.0% of portfolio
Latest Institutional Activity in CHNG
Top Purchases
Top Sells
About CHNG
Change Healthcare Inc., an independent healthcare technology company, provides data and analytics-driven solutions to enhance clinical, financial, administrative, and patient engagement outcomes in the United States healthcare system. It operates through three segments: Software and Analytics, Network Solutions, and Technology-Enabled Services. The Software and Analytics segment offers software and analytics solutions for revenue cycle management, provider network management, payment accuracy, clinical decision support, value-based payment, consumer engagement, risk adjustment and quality performance, and imaging and clinical workflow. The Network Solutions segment provides solutions for financial, administrative, and clinical and pharmacy transactions; connected consumer health; network; electronic payments; data; pharmacy; and aggregation and analytics of clinical and financial data. The Technology-Enabled Services segment offers solutions for financial and administrative management, value-based care, communication and payment, pharmacy benefits administration, and healthcare consulting. The company serves commercial insurers, private insurers, BlueCross Blue Shield plans, Medicare/Medicaid plans, provider-sponsored payers, third party administrators, emerging technology and data-driven health plans, and other specialty health benefits insurers, as well as hospitals and health systems, physician practices, dentists, pharmacies, skilled nursing facilities, home health agencies, telehealth providers, senior care facilities, laboratories, and other healthcare providers. Change Healthcare Inc. was incorporated in 2016 and is headquartered in Nashville, Tennessee.
Insider Transactions at CHNG
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 03
2022
|
Philip M Pead Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
102,642
-80.51%
|
$2,566,050
$25.75 P/Share
|
Oct 03
2022
|
Paul Rareshide SVP, Corporate Controller |
SELL
Sale (or disposition) back to the issuer
|
Direct |
49,968
-76.25%
|
$1,249,200
$25.75 P/Share
|
Oct 03
2022
|
Paul Rareshide SVP, Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
9,177
+50.0%
|
-
|
Oct 03
2022
|
Nella Domenici Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
29,280
-100.0%
|
-
|
Oct 03
2022
|
Kriten Joshi Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
569,000
-80.45%
|
$14,225,000
$25.75 P/Share
|
Oct 03
2022
|
Kriten Joshi Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,888
+50.0%
|
-
|
Oct 03
2022
|
Neil E. De Crescenzo President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,557,392
-81.45%
|
$38,934,800
$25.75 P/Share
|
Oct 03
2022
|
Neil E. De Crescenzo President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
220,264
+50.0%
|
-
|
Oct 03
2022
|
Thomas Laur Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
264,489
-77.38%
|
$6,612,225
$25.75 P/Share
|
Oct 03
2022
|
Thomas Laur Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,888
+50.0%
|
-
|
Oct 03
2022
|
Fredrik J Eliasson EVP & CFO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
140,000
-100.0%
|
$3,500,000
$25.75 P/Share
|
Oct 03
2022
|
Fredrik J Eliasson EVP & CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
715,104
-78.71%
|
$17,877,600
$25.75 P/Share
|
Oct 03
2022
|
Fredrik J Eliasson EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
119,309
+50.0%
|
-
|
Oct 03
2022
|
Diana Mckenzie Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
40,706
-100.0%
|
-
|
Oct 03
2022
|
Bansi Nagji Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
39,280
-62.73%
|
$982,000
$25.75 P/Share
|
Oct 03
2022
|
Thomas Mcenery EVP & Chief Marketing Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
316,240
-89.21%
|
$7,906,000
$25.75 P/Share
|
Oct 03
2022
|
Thomas Mcenery EVP & Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
69,908
+50.0%
|
-
|
Oct 03
2022
|
Robert Zollars Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
40,706
-100.0%
|
-
|
Oct 03
2022
|
Phillip W. Roe Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
40,706
-100.0%
|
-
|
Oct 03
2022
|
Linda Whitley Taylor EVP & Chief People Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
230,562
-77.21%
|
$5,764,050
$25.75 P/Share
|